We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Barinthus Biotherapeutics plc (BRNS) ADR Each Rep 1 Ord Share Spon

Sell:$1.26 Buy:$1.55 Change: $0.0503 (3.87%)
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Sell:$1.26
Buy:$1.55
Change: $0.0503 (3.87%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Sell:$1.26
Buy:$1.55
Change: $0.0503 (3.87%)
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Barinthus Biotherapeutics plc, formerly Vaccitech plc, is a clinical-stage biopharmaceutical company. It is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. It is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.

Contact details

Address:
The Schrdinger Building
Heatley Road, The Oxford Science Park
DIDCOT
OX11 0DF
United Kingdom
Telephone:
+44 (1865) 818808
Website:
https://www.barinthusbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BRNS
ISIN:
US91864C1071
Market cap:
$57.38 million
Shares in issue:
77.99 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • William Enright
    Chief Executive Officer, Director
  • Gemma Brown
    Chief Financial Officer, Company Secretary
  • Nadege Pelletier
    Chief Scientific Officer
  • Graham Griffiths
    Chief Business Officer
  • Leon Hooftman
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.